Biotech Archives - Page 38 of 795

1 minute read

Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024

May 9, 9:17 AM

Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at

ASND

1 minute read

Akoya Biosciences And NeraCare Enter Exclusive Agreement To Enable Personalized Therapy Selection For Early-Stage Melanoma Patients

By Benzinga Newsdesk

May 9, 9:02 AM

Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which

AKYA

1 minute read

Rani Therapeutics To Present Data On Oral Delivery Of An Ustekinumab Biosimilar Via The RaniPill Capsule At Digestive Disease Week 2024

By Benzinga Newsdesk

May 9, 9:00 AM

Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical

RANI

2 minute read

Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.

By Benzinga Newsdesk

May 9, 8:56 AM

-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with

MNMD

2 minute read

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes For IkT-001Pro For Pulmonary Arterial Hypertension

By Benzinga Newsdesk

May 9, 8:52 AM

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension –BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase

IKT

2 minute read

EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares

By Vandana Singh

May 9, 7:30 AM

Alzamend Neuro seals $500,000 Series A Convertible Preferred Stock deal with an investor. Plans to raise up to $25 million for clinical trials and working capital.

ALZN

1 minute read

Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: ‘Digital Medicine With Incredible Potential’

By Shanthi Rexaline

May 9, 5:01 AM

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

ARCT

1 minute read

Oculis Announces Completion Of Enrollment In Phase 2 Randomized Controlled ACUITY Trial With OCS-05 For Acute Optic Neuritis

By Benzinga Newsdesk

May 8, 5:46 PM

Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON) Oculis also aims to complete an IND submission for OCS-05 in the

OCS

2 minute read

Crinetics Pharmaceuticals To Present Advancements From Atumelnant And Paltusotine Development Programs At ENDO 2024 June 1-4, 2024

By Benzinga Newsdesk

May 8, 5:44 PM

Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing's Syndrome Trial Data from Phase 3 PATHFNDR 1 and

CRNX